title: Effect of ring-constrained phenylpropyloxyethylamines on sigma receptors.
abstract: A series of ring-constrained phenylpropyloxyethylamines, partial opioid structure analogs and derivatives of a previously studied sigma (σ) receptor ligand, was synthesized and evaluated at σ and opioid receptors for receptor selectivity. The results of this study identified several compounds with nanomolar affinity at both σ receptor subtypes. Compounds 6 and 9 had the highest selectivity for both σ receptor subtypes, compared to μ opioid receptors. In addition, compounds 6 and 9 significantly reduced the convulsive effects of cocaine in mice, which would be consistent with antagonism of σ receptors.
authors.affiliation: Department of Pharmaceutical Sciences, University of Maryland, School of Pharmacy, 20 N. Pine Street, Baltimore, MD 21201, USA.
authors.forename: Lidiya
authors.initials: L
authors.lastname: Stavitskaya
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Seminerio
authors.forename: Jason R
authors.initials: JR
authors.lastname: Healy
authors.forename: Bahar
authors.initials: B
authors.lastname: Noorbakhsh
authors.forename: Rae R
authors.initials: RR
authors.lastname: Matsumoto
authors.forename: Andrew
authors.initials: A
authors.lastname: Coop
mesh_terms: D000818:Animals; D003042:Cocaine / Q000737:chemistry / Q000633:toxicity; D003292:Convulsants / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D003511:Cyclohexanols / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use; D005021:Ethylamines / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use; D051379:Mice; D010627:Phenethylamines / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use; D011437:Propylamines / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use; D011485:Protein Binding; D017480:Receptors, sigma / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy
chemical_list: C587052:2-(methyl(3-phenylpropyl)amino)cyclohexanol; C587051:2-(methyl(phenethyl)amino)cyclohexanol; D003292:Convulsants; D003511:Cyclohexanols; D005021:Ethylamines; D010627:Phenethylamines; D011437:Propylamines; D017480:Receptors, sigma; D003042:Cocaine
keywords: Antagonists; Opioid; Phenylpropyloxyethylaminesl; Sigma
references.citation: J Pharmacol Exp Ther. 2011 Nov;339(2):662-77
references.pmid: 21859929
references.citation: Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8196-9
references.pmid: 10393971
references.citation: Eur Neuropsychopharmacol. 2008 Dec;18(12):871-81
references.pmid: 18755577
references.citation: J Pharmacol Sci. 2005 Mar;97(3):317-36
references.pmid: 15750289
references.citation: Neuropharmacology. 2002 Jun;42(8):1043-55
references.pmid: 12128006
references.citation: Pharmaceuticals (Basel). 2011;4(6):880-914
references.pmid: 21904468
references.citation: Neuroreport. 2000 Sep 11;11(13):2885-8
references.pmid: 11006959
references.citation: Behav Pharmacol. 2011 Sep;22(5-6):525-30
references.pmid: 21808192
references.citation: Biochem Pharmacol. 2001 Aug 1;62(3):349-55
references.pmid: 11434908
references.citation: J Pharmacol Exp Ther. 1976 Jun;197(3):517-32
references.pmid: 945347
references.citation: Nat Commun. 2011 Jul 05;2:380
references.pmid: 21730960
references.citation: Bioorg Med Chem Lett. 2002 Feb 11;12(3):497-500
references.pmid: 11814827
references.citation: Neuropsychopharmacology. 2013 Mar;38(4):605-15
references.pmid: 23187725
references.citation: Bioorg Med Chem. 2012 Jul 15;20(14):4556-63
references.pmid: 22677527
references.citation: J Neurosci. 1995 Jan;15(1 Pt 1):117-34
references.pmid: 7823122
references.citation: Mol Pharmacol. 1993 Feb;43(2):139-48
references.pmid: 8429820
references.citation: Bioorg Med Chem. 2004 Oct 1;12(19):5019-30
references.pmid: 15351386
references.citation: Trends Pharmacol Sci. 1992 Mar;13(3):85-6
references.pmid: 1315463
references.citation: NIDA Res Monogr. 1998 Mar;178:440-66
references.pmid: 9686407
references.citation: Neurosci Biobehav Rev. 2002 Jun;26(4):499-527
references.pmid: 12204195
references.citation: J Pharmacol Exp Ther. 2010 May;333(2):491-500
references.pmid: 20100904
references.citation: Expert Rev Clin Pharmacol. 2009 Jul;2(4):351-8
references.pmid: 22112179
references.citation: Eur J Pharmacol. 1995 Jul 14;280(3):301-10
references.pmid: 8566098
references.citation: Eur J Pharmacol. 1994 Jun 15;268(1):9-18
references.pmid: 7925616
references.citation: Psychopharmacology (Berl). 2004 Sep;175(2):154-62
references.pmid: 14985920
references.citation: Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):491-6
references.pmid: 11149946
references.citation: Drug Alcohol Depend. 2011 Oct 1;118(1):40-7
references.pmid: 21420799
references.citation: Mol Pharmacol. 1987 Dec;32(6):772-84
references.pmid: 2826991
references.citation: Eur J Pharmacol. 2001 Apr 6;417(1-2):R1-2
references.pmid: 11301071
references.citation: J Pharmacol Exp Ther. 2000 Jun;293(3):788-98
references.pmid: 10869377
references.citation: Psychopharmacology (Berl). 2004 Jul;174(3):301-19
references.pmid: 15197533
references.citation: J Neurochem. 1998 Feb;70(2):443-51
references.pmid: 9453537
references.citation: Eur J Pharmacol. 2001 Jan 12;411(3):261-73
references.pmid: 11164383
references.citation: Eur J Pharmacol. 2003 May 23;469(1-3):1-12
references.pmid: 12782179
references.citation: Curr Genet. 2002 Oct;42(1):59-65
references.pmid: 12420147
references.citation: Brain Res. 1990 Sep 17;527(2):244-53
references.pmid: 2174717
references.citation: Pharmacol Biochem Behav. 1990 Nov;37(3):557-9
references.pmid: 1965044
references.citation: Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
references.pmid: 4202581